These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 20412543)

  • 21. Approaches to risk-benefit assessment of seafood consumption: lessons learned from an evidence scan.
    Santillana Farakos SM; Heilman J; Abt E; Dennis S
    Front Nutr; 2024; 11():1290680. PubMed ID: 38425480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discrepancies between multicriteria decision analysis-based ranking and intuitive ranking for pharmaceutical benefit-risk profiles in a hypothetical setting.
    Hoshikawa K; Ono S
    J Clin Pharm Ther; 2017 Feb; 42(1):80-86. PubMed ID: 27914099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature.
    Brett Hauber A; Fairchild AO; Reed Johnson F
    Appl Health Econ Health Policy; 2013 Aug; 11(4):319-29. PubMed ID: 23637054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A unified framework for classification of methods for benefit-risk assessment.
    Najafzadeh M; Schneeweiss S; Choudhry N; Bykov K; Kahler KH; Martin DP; Gagne JJ
    Value Health; 2015 Mar; 18(2):250-9. PubMed ID: 25773560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transitioning the second-generation antihistamines to over-the-counter status: a cost-effectiveness analysis.
    Sullivan PW; Follin SL; Nichol MB
    Med Care; 2003 Dec; 41(12):1382-95. PubMed ID: 14668671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.
    Mt-Isa S; Hallgreen CE; Wang N; Callréus T; Genov G; Hirsch I; Hobbiger SF; Hockley KS; Luciani D; Phillips LD; Quartey G; Sarac SB; Stoeckert I; Tzoulaki I; Micaleff A; Ashby D;
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):667-78. PubMed ID: 24821575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the Risks and Benefits of New Chemical Entities Approved by the US Food and Drug Administration (FDA) and Subsequently Withdrawn From the US Market.
    Patriarca PA; Van Auken RM; Kebschull SA
    Ther Innov Regul Sci; 2018 Sep; 52(5):649-655. PubMed ID: 29714557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accelerated approval of drugs: ethics versus efficacy.
    Chary KV; Pandian K
    Indian J Med Ethics; 2017; 2(4):244-247. PubMed ID: 28661403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis.
    Lynd LD; O'brien BJ
    J Clin Epidemiol; 2004 Aug; 57(8):795-803. PubMed ID: 15485731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Sponsor's Perspective on the Contribution of Regulatory-Required Observational Post-Marketing Studies to Understanding Human Drug Product Benefit/Risk in Japan.
    Wolter KD; Kamatani A; Suzuki Y; Imaeda T; Dagher R; Safferman A; Junor R
    Pharmaceut Med; 2024 May; 38(3):217-224. PubMed ID: 38555545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines.
    Pane J; Coloma PM; Verhamme KM; Sturkenboom MC; Rebollo I
    Drug Saf; 2017 Jan; 40(1):37-47. PubMed ID: 27928726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives.
    Felli JC; Noel RA; Cavazzoni PA
    Med Decis Making; 2009; 29(1):104-15. PubMed ID: 18812582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple Myeloma.
    Raju GK; Gurumurthi K; Domike R; Kazandjian D; Landgren O; Blumenthal GM; Farrell A; Pazdur R; Woodcock J
    Clin Pharmacol Ther; 2018 Jan; 103(1):67-76. PubMed ID: 28901535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.